Summary of all assay results for VITT-positive and VITT-negative patients
| VITT-positive samples (n = 43) . | ||||||
|---|---|---|---|---|---|---|
| . | IgG/A/M-EIA . | PF4-EIA . | PF4/Hep-EIA . | SRA* (n = 42) . | PF4-SRA . | PF4/Hep-SRA* (n = 26) . |
| Total results negative | 0/43 (0%) | 0/43 (0%) | 0/43 (0%) | 35/42 (83.3%) | 0/43 (0%) | 14/26 (53.8%) |
| Total results positive | 43/43 (100%) | 43/43 (100%) | 43/43 (100%) | 7/42 (16.7%) | 43/43 (100%) | 12/26 (46.2%) |
| VITT-positive samples (n = 43) . | ||||||
|---|---|---|---|---|---|---|
| . | IgG/A/M-EIA . | PF4-EIA . | PF4/Hep-EIA . | SRA* (n = 42) . | PF4-SRA . | PF4/Hep-SRA* (n = 26) . |
| Total results negative | 0/43 (0%) | 0/43 (0%) | 0/43 (0%) | 35/42 (83.3%) | 0/43 (0%) | 14/26 (53.8%) |
| Total results positive | 43/43 (100%) | 43/43 (100%) | 43/43 (100%) | 7/42 (16.7%) | 43/43 (100%) | 12/26 (46.2%) |
| VITT-negative samples (n = 113) . | ||||||
|---|---|---|---|---|---|---|
| . | IgG/A/M-EIA . | PF4-EIA . | PF4/Hep-EIA . | SRA* (n = 111) . | PF4-SRA . | PF4/Hep-SRA* (n = 7) . |
| Total results negative | 108/113 (95.6%) | 109/113 (96.5%) | 110/113 (97.3%) | 111/111 (100%) | 113/113 (0%) | 7/7 (100%) |
| Total results positive | 5/113 (4.4%) | 4/113 (3.5%) | 3/113 (2.7%) | 0/111 (0%) | 0/113 (0%) | 0/7 (0%) |
| VITT-negative samples (n = 113) . | ||||||
|---|---|---|---|---|---|---|
| . | IgG/A/M-EIA . | PF4-EIA . | PF4/Hep-EIA . | SRA* (n = 111) . | PF4-SRA . | PF4/Hep-SRA* (n = 7) . |
| Total results negative | 108/113 (95.6%) | 109/113 (96.5%) | 110/113 (97.3%) | 111/111 (100%) | 113/113 (0%) | 7/7 (100%) |
| Total results positive | 5/113 (4.4%) | 4/113 (3.5%) | 3/113 (2.7%) | 0/111 (0%) | 0/113 (0%) | 0/7 (0%) |
Tested on a smaller VITT patient cohort (SRA n = 153, PF4/hep-SRA n = 33) compared with other assays (n = 156).